Company Filing History:
Years Active: 2000
Title: **The Innovations of Allen Laughon in TGF-β Pathway Research**
Introduction
Allen Laughon, a prominent inventor based in Madison, Wisconsin, has made significant contributions in the field of biotechnology. With one patent to his name, Laughon's innovations have the potential to influence the understanding and manipulation of the TGF-β signaling pathway, which plays a crucial role in various biological processes.
Latest Patents
His patent, titled "Compositions and methods for identifying and testing TGF-β pathway," presents novel compositions and methodologies for identifying agonists and antagonists of the TGF-β pathway. This invention notably includes compositions that comprise Mothers against DPP (MAD) proteins and related Smad polypeptides, which exhibit sequence-specific DNA-binding activity. Additionally, the patent introduces a novel DNA sequence (SEQ ID NO:19; SEQ ID NO:20; SEQ ID NO:21) that is bound with high affinity by Drosophila MAD protein. This discovery is pivotal for identifying compounds capable of enhancing or interfering with MAD protein-DNA binding.
Career Highlights
Allen Laughon's career has been highlighted by his role in advancing biotechnology through innovative research. Currently working with Ophidian Pharmaceuticals, Inc., he has distinguished himself as a leading figure in the exploration of complex biochemical pathways, particularly in the context of therapeutic applications. His work has implications for drug development and disease treatment by providing foundational methods for screening TGF-β pathway modulators.
Collaborations
In his pursuit of innovation, Laughon collaborates closely with colleagues such as Kirby Johnson and Jaeseob Kim. These partnerships reflect a collaborative spirit in research and development, enabling comprehensive approaches to complex scientific problems. Together, they contribute to advancements in understanding and manipulating biological pathways, enhancing the potential for medical breakthroughs.
Conclusion
Allen Laughon's work exemplifies the fusion of scientific inquiry and practical application in biotechnology. His patent on TGF-β pathway identification and testing methods represents a valuable advancement in the field, showcasing the importance of innovation in medicine. As he continues his work with Ophidian Pharmaceuticals, his contributions will undoubtedly influence future research and therapeutic strategies within this crucial area of study.